Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous adipose-derived stem cells for scars and cutis laxa
2016-004110-10Phase 2Completed
- Sponsor
- Medical University of Warsaw
- Start
- May 2017
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous adipose-derived stromal vascular fraction and autologous adipose-derived mesenchymal stromal cells in severe cutaneous adverse reactions (SCAR), cutis laxa and cutaneous fibrosis (2 arms), sponsored by Medical University of Warsaw. Primary endpoint: Time to 50% increase in patient quality of life. Started May 2017; status: completed.
02
Drugs
autologous adipose-derived stromal vascular fractionautologous adipose-derived mesenchymal stromal cells
03
Conditions
severe cutaneous adverse reactions (SCAR)cutis laxacutaneous fibrosis
Beyond the preview
Go deeper on 2016-004110-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004110-10.